Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First‐Line Gastric Cancer and Elevated Plasma VEGF‐A

To simulate clinical trials to assess overall survival (OS) benefit of bevacizumab in combination with chemotherapy in selected patients with gastric cancer (GC), a modeling framework linking OS with tumor growth inhibition (TGI) metrics and baseline patient characteristics was developed. Various TG...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, K, Claret, L, Piao, Y, Hegde, P, Joshi, A, Powell, JR, Jin, J, Bruno, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961078/
https://www.ncbi.nlm.nih.gov/pubmed/27404946
http://dx.doi.org/10.1002/psp4.12064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961078/
https://www.ncbi.nlm.nih.gov/pubmed/27404946
http://dx.doi.org/10.1002/psp4.12064

Ejemplares similares